97354 ⎘
Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
ALK7 ANTAGONISTS AND USES THEREOF
#602Multivalent and monovalent multispecific complexes and their uses
#603Methods and compositions for transducing lymphocytes and regulated expansion thereof
#604Method for modulating car-induced immune cells activity
#605Car expression vector and car-expressing T cells
#606Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
#607GLYPICAN-3 SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
#608Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapy
#609Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof
#610Oncolytic adenovirus encoding a therapeutic protein or active fragment
#611Cell-targeted cytotoxic constructs
#612Compositions and methods for tumor transduction
#613Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
#614Neonatal Fc receptor binding dimer and methods of use
#615Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy
#616Soluble engineered monomeric Fc
#617Modified glycoproteins
#618Desmoglein 2 (DSG2) binding proteins and uses therefor
#619T-cell redirecting bispecific antibodies for treatment of disease
#620Compositions and methods for modulating T-cell mediated immune response
#621Binding-triggered transcriptional switches and methods of use thereof
#622Fusions of antibodies to CD38 and attenuated interferon alpha
#623Protein and protein conjugate for diabetes treatment, and applications thereof
#624METHODS AND COMPOSITIONS USING KLOTHO-FGF FUSION POLYPEPTIDES
#625Methods of making T cell compositions
#626Targeted conformationally-constrained kinked endosomal disrupting peptides
#627CONSTANT REGION ANTIBODY FUSION PROTEINS AND COMPOSITIONS THEREOF
#628SUBSET-OPTIMIZED CHIMERIC ANTIGEN RECEPTOR-CONTAINING T-CELLS
#629Delivery of therapeutic agents by a collagen binding protein
#630Engineered cells for adoptive cell therapy
#631Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen
#632METHODS AND COMPOSITIONS RELATING TO TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
#633Methods of treating cancer by administering IGF-IR binding molecules
#634BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
#635Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
#636Macrophage CAR (MOTO-CAR) in immunotherapy
#637Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
#638Antigen binding formats for use in therapeutic treatments or diagnostic assays
#639Chimeric antigen receptor and methods of use thereof
#640Methods for improving the efficacy and expansion of immune cells
#641Screening of protein candidates
#642Antibody/drug conjugates and methods of use
#643TEM8 ANTIBODIES AND METHODS OF USE
#644Human cytolytic fusion proteins
#645Chimeric antigen receptors targeting CD-19
#646Bispecific chimeric antigen receptors and methods of use thereof to treat cancer
#647Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
#648Immunoconjugates
#649High affinity NY-ESO T cell receptors
#650Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
#651Targeted human-interferon fusion proteins
#652Method for in situ inhibition of regulatory T cells
#653Erythrocyte-binding therapeutics
#654Adenoviral vector vaccine
#655Detecting a therapeutic cell
#656Fusion protein for treating rejection reaction in transplantation
#657LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
#658Oncolytic adenovirus encoding a B7 protein or active fragment
#659Polypeptides and uses thereof for reducing CD95-mediated cell motility
#660Ligands modified by circular permutation as agonists and antagonists
#661Interleukin 15 as selectable marker for gene transfer in lymphocytes
#662EXPRESSION OF TRIPLE-HELICAL COLLAGEN-LIKE PRODUCTS IN E.COLI
#663Degradation of Beta-Amyloid Proteins With Keratinase
#664IMMUNE-CHECKPOINT INHIBITORS FOR USE IN THE TREATMENT OF BLOOD-BORNE CANCERS
#665Fusion proteins and combination vaccines comprising protein E and pilin A
#666T-cell redirecting bispecific antibodies for treatment of disease
#667Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide, methods and uses therefor
#668Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same
#669Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof
#670Chimeric antigen receptor (CAR) signalling system
#671Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof
#672Compositions and methods for treating cancer
#673IL-15 variants and uses thereof
#674Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes
#675Artificial signal peptide
#676Methods for reducing immune responses
#677Compositions for inducing antigen-specific tolerance
#678Methods for induction of antigen-specific immune tolerance
#679Compositions for generating immune tolerance by targeting erythrocytes
#680Anti-TOSO chimeric antigen receptor and its use
#681P97 FUSION PROTEINS
#682Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
#683Costimulatory chimeric antigen receptor T cells targeting IL13Rα2
#684Molecular constructs for treating central nervous system diseases
#685Molecular constructs for treating infectious diseases
#686Molecular constructs with targeting and effector moieties for treating infectious diseases
#687Molecular constructs with targeting and effector moieties comprising an SCFV specific for ectodomain of transferrin-1 receptor and fingolimod
#688Peptide core-based multi-arm linkers for treating infectious diseases
#689Peptide core-based multi-arm linkers for treating central nervous system diseases
#690Peptide core-based multi-arm linkers and their applications
#691Pseudotyped lentiviral vectors
#692Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
#693Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
#694Receptor targeting constructs and uses thereof
#695Vaccines against HPV and HPV-related diseases
#696SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF
#697IL-15 and IL-15R\alpha sushi domain based immunocytokines
#698Human mesothelin chimeric antigen receptors and uses thereof
#699Bi-specific T-cell engager specific for BCMA
#700Follistatin-related fusion proteins
#701Promiscuous HPV16-derived T helper epitopes for immunotherapy
#702Compositions and methods for delivering inhibitory oligonucleotides
#703POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION
#704Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
#705Fusion protein comprising interleukin-2 and interleukin-33
#706EPHA3 And multi-valent targeting of tumors
#707CELL
#708Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
#709Cell
#710Cell
#711Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
#712CD27 single chain molecules and encoding nucleic acids
#713SOLUBLE CTLA-4 MOLECULES AND DERIVATIVES THEREOF FOR TREATMENT OF MINIMAL CHANGE DISEASE
#714Binding-triggered transcriptional switches and methods of use thereof
#715CTLA4-Ig immunoadhesins
#716Immunoconjugates
#717Modified binding proteins inhibiting the VEGF-A receptor interaction
#718Desmoglein 2 (DSG2) binding proteins and uses therefor
#719Fusion proteins and combination vaccines comprising Protein E and Pilin A
#720Fusion polypeptides comprising mucin-domain polypeptide linkers
#721Vaults engineered for hydrophobic drug delivery
#722Composition comprising a mixture of CD95-Fc isoforms
#723CHIMERIC ANTIGEN RECEPTOR TARGETING OF TUMOR ENDOTHELIUM
#724IL-1beta propeptide and IL-1Ra chimera and methods of using the same
#725Compositions and methods for treatment of cancer
#726Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
#727Compositions and methods for treatment of cancer
#728SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOF
#729Chimeric antigen receptor and methods of use thereof
#730Methods of making chimeric antigen receptor-expressing cells
#731SIRP-α immunoglobulin fusion proteins
#732T-cell redirecting bispecific antibodies for treatment of disease
#733Binding molecules for BCMA and CD3
#734PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1
#735THERAPEUTIC FUSION PROTEIN
#736Antibody multimerization technologies
#737Trimeric antigen binding molecules
#738Compositions and methods for treatment of cancer
#739Insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands
#740NOGO Receptor Antagonists
#741Targeting of human interferon antagonists
#742Targeted modified TNF family members
#743Antibody targeting through a modular recognition domain
#744Peptide linkers for polypeptide compositions and methods for using same
#745Targeted therapeutic proteins
#746COMPOSITIONS AND METHODS TO MODIFY CELLS FOR THERAPEUTIC OBJECTIVES
#747Construction and application of bispecific antibody HER2xCD3
#748CD19 specific chimeric antigen receptor and uses thereof
#749Antigen binding protein and its use as addressing product for the treatment of cancer
#750Interferon lambda-antibody complexes
#751Methods for transduction and cell processing
#752Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
#753CARTILAGE-BINDING FUSION PROTEINS
#754Methods for engineering allogeneic and highly active t cell for immunotherapy
#755CHIMERIC FVII-XTEN MOLECULES AND USES THEREOF
#756CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
#757Polypeptide, anti-VEGF antibody, and anti-c-Met/anti-VEGF bispecific antibodies comprising the same
#758Removal of Cancer Cells by Circulating Virus-Specific Cytotoxic T-Cells Using Cancer Cell Targeted MHC Class 1 Compromising Multi-Function Proteins
#759Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof
#760Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
#761Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
#762Administration of kynurenine depleting enzymes for tumor therapy
#763Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
#764Polypeptides
#765Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy
#766METHODS AND THERAPEUTICS COMPRISING LIGAND-TARGETED ELPs
#767Effective generation of tumor-targeted T cells derived from pluripotent stem cells
#768Oligomers for TNF superfamily inhibition
#769Chimeric polypeptides comprising G protein-coupled receptors and VHH antibodies
#770Nucleic acid construct encoding an agonistic anti-CD40 antibody and a type I interferon
#771METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL STROMAL TUMOR (GIST)
#772Fusion proteins that facilitate cancer cell destruction
#773METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF
#774Compositions and methods for immunotherapy
#775Method and device for producing crude copper
#776M971 chimeric antigen receptors
#777Compositions and methods
#778Compositions and methods for antigen targeting to CD180
#779Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cells
#780Multi-level specific targeting of cancer cells
#781FUSION PROTEINS AND METHODS FOR TREATING, PREVENTING OR AMELIORATIONG PAIN
#782HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF
#783Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)
#784Protein and protein conjugate for diabetes treatment, and applications thereof
#785CHIMERIC NEUREGULINS AND METHOD OF MAKING AND USE THEREOF
#786Modified vaccinia virus strains for use in diagnostic and therapeutic methods
#787Peptide conjugates for treating pain
#788Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System
#789Methods for treating diseases with peptides that inhibit IGF-1
#790Methods of treating disease with fusion molecules comprising IL-15 variants
#791Cytokine-based fusion proteins for treatment of immune disorders
#792Cancer treatment and monitoring methods using OX40 agonists
#793Multi-specific Fab fusion proteins comprising a CD3-binding Fab fragment with N-terminal fusion to binding domains and methods of use
#794Soluble engineered monomeric Fc
#795Peptides for inhibiting tumor growth
#796Antigen binding protein and its use as addressing product for the treatment of cancer
#797Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
#798Methods and compositions for generating bioactive assemblies of increased complexity and uses
#799Compositions and methods for delivering inhibitory oligonucleotides
#800Erythrocyte-binding therapeutics
#801Multivalent fibronectin based scaffold domain proteins
#802Targeted human-interferon fusion proteins
#803Cell growth-promoting peptide and use thereof
#804Treating macular degeneration using antibodies to aminophospholipids
#805Method of reversibly staining a target cell
#806Suppression of cancer
#807Complexation of fatty acid-conjugated molecules with albumin
#808Anti-CD22 chimeric antigen receptors
#809Lytic domain fusion constructs and methods of making and using same
#810Fusion proteins and methods of use
#811HSA-related compositions and methods of use
#812Nogo receptor antagonists and methods of increasing neurite outgrowth
#813Modified binding proteins inhibiting the VEGF-A receptor interaction
#814Fusion molecules and IL-15 variants
#815Fusion peptide comprising dhFas-1 domain and MMP substrate and use thereof for preventing and treating rheumatoid arthritis
#816Therapeutic fusion proteins
#817Method of determining, identifying or isolating cell-penetrating peptides
#818Fusion protein comprising diphtheria toxin non-toxic mutant CRM197 or fragment thereof
#819Multi-chain chimeric antigen receptor and uses thereof
#820Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders
#821Polypeptides and vectors for targeting HER2/expressing cells and uses thereof
#822Chimeric neuregulins and method of making and use thereof
#823Fusion proteins and methods of use
#824FUSION PROTEINS
#825Targeted therapeutic proteins
#826Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy
#827Use of chimeric antigen receptor-modified T-cells to treat cancer
#828Interleukin 15 as selectable marker for gene transfer in lymphocytes
#829Methods and compositions for treating HIV
#830Fusion peptides comprising multi-functional peptidic solubility tags for efficient production, processing and surface applications
#831Interferon lambada-antibody complexes
#832Method for uses of proinsulin transferrin fusion proteins as prodrugs
#833Peptide derivatives, preparation and uses thereof
#834TRAIL R2-specific multimeric scaffolds
#835Multimeric Fc receptor polypeptides
#836Interferon analogs
#837High affinity NY-ESO T cell receptors
#838HSA-related compositions and methods of use
#839Chimeric Polypeptides Useful in Proximal and Dynamic High-Throughput Screening Methods
#840Multivalent fibronectin based scaffold domain proteins
#841COMPLEXES COMPRISING MHC CLASS I FUSION POLYPEPTIDES AND ANTIGEN-SPECIFIC ANTIBODIES AND METHODS OF USE
#842Methods and compositions for the treatment and prevention of cancer
#843Multi-specific FAB fusion proteins and methods of use
#844Low density lipoprotein receptor-mediated siRNA delivery
#845OLIGOMERIC RECEPTOR LIGAND PAIR MEMBER COMPLEXES
#846Methods of generating immune responses with compositions comprising an adenoviral expression vector comprising a CD40L fusion protein
#847Immunoconjugates
#848METHOD OF DELIVERING RNA INTERFERENCE AND USES THEREOF
#849Method for inducing angiogenesis in an infarcted heart by administering a coiled coil chimeric molecule
#850Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#851Peptide linkers for polypeptide compositions and methods for using same
#852Fusion molecules and IL-15 variants
#853Composition comprising an adenoviral expression vector comprising a CD40L fusion protein for generating immune responses
#854Erythrocyte-binding therapeutics
#855Screening of protein candidates
#856Chimaeric protein
#857Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
#858Targeted therapeutic proteins
#859Polypeptides that Bind TRAIL-R1 and TRAIL-R2
#860Method for inhibiting growth of chondrocytes in a subject by inhibiting IGF-1
#861CONSTRUCTS FOR DELIVERY OF THERAPEUTIC AGENTS TO NEURONAL CELLS
#862Expression of triple-helical collagen-like products in
#863B7-H1 antibodies and method of use
#864Compositions of and methods of using ligand dimers
#865Erythrocyte-binding therapeutics
#866Polypeptides that Bind TRAIL-R1 and TRAIL-R2
#867Anticoagulant fusion protein anchored to cell membrane
#868Method for Uses of Protein Precursors as Prodrugs
#869Human serum albumin linkers and conjugates thereof
#870Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof
#871Multi-level specific targeting of cancer cells with IL-13
#872Modified vaccinia virus strains for use in diagnostic and therapeutic methods
#873Alpha 1-antitrypsin compositions and methods of making and using same
#874CTLA4-Ig immunoadhesins
#875Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
#876Compositions and methods for identifying antigens which elicit an immune response
#877Chimeric activators: quantitatively designed protein therapeutics and uses thereof
#878COMPOSITIONS CONTAINING THROMBOMODULIN DOMAINS AND USES THEREOF
#879SUPPRESSION OF CANCER
#880High affinity NY-ESO T cell receptors
#881Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
#882Low density lipoprotein receptor-mediated siRNA delivery
#883METHODS AND COMPOSITIONS USING FGF23 FUSION PPOLYPEPTIDES
#884Methods and compositions for generating bioactive assemblies of increased complexity and uses
#885ADENOVIRUS PARTICLES HAVING A CHIMERIC ADENOVIRUS SPIKE PROTEIN, USE THEREOF AND METHODS FOR PRODUCING SUCH PARTICLES
#886Antibody Targeting Through a Modular Recognition Domain
#887Antigenic compositions and use of same in the targeted delivery of nucleic acids
#888TGF-Beta Antagonist Multi-Target Binding Proteins
#889TREATING CANCER STEM CELLS USING TARGETED CARGO PROTEINS
#890NK-1 Receptor Mediated Delivery of Agents to Cells
#891Single-chain TNFSF fusion polypeptides
#892Multi-Specific Binding Proteins Targeting B Cell Disorders
#893INSULIN-LIKE GROWTH FACTOR FUSION PROTEINS
#894Compositions and methods for delivering inhibitory oligonucleotides
#895Recombinant bacteriophage and methods for their use
#896TOLERIZING AGENTS
#897Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
#898Polypeptides that Bind IL-23R
#899Combinatorial Libraries Based on C-type Lectin-like Domain
#900ADAPTER MOLECULE FOR THE DELIVERY OF ADENOVIRUS VECTORS